Takeda Pharmaceutical (TAK) Expected to Announce Quarterly Earnings on Thursday

Takeda Pharmaceutical (NYSE:TAK) is expected to post its Q3 2026 results before the market opens on Thursday, January 29th. Analysts expect Takeda Pharmaceutical to post earnings of $0.55 per share and revenue of $7.8144 billion for the quarter. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, January 29, 2026 at 5:30 AM ET.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The company had revenue of $7.30 billion during the quarter, compared to analysts’ expectations of $8.01 billion. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $16.11 on Thursday. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61. The stock has a market cap of $51.25 billion, a PE ratio of 201.31 and a beta of 0.03. The company’s fifty day moving average is $15.06 and its 200 day moving average is $14.72. Takeda Pharmaceutical has a 52 week low of $12.80 and a 52 week high of $16.48.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its position in Takeda Pharmaceutical by 56.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Advisory Services Network LLC bought a new position in shares of Takeda Pharmaceutical during the third quarter valued at approximately $74,000. Larson Financial Group LLC raised its holdings in shares of Takeda Pharmaceutical by 43.7% during the third quarter. Larson Financial Group LLC now owns 7,823 shares of the company’s stock valued at $115,000 after acquiring an additional 2,379 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Takeda Pharmaceutical in the second quarter valued at $174,000. Finally, BNP Paribas Financial Markets boosted its holdings in Takeda Pharmaceutical by 1,652.2% in the second quarter. BNP Paribas Financial Markets now owns 11,845 shares of the company’s stock valued at $183,000 after acquiring an additional 11,169 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Upgrades and Downgrades

TAK has been the topic of several analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Morgan Stanley initiated coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating on the stock. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Takeda Pharmaceutical presently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.